HRP20151145T1 - Fosfolipidima obogaä†ene vezikule koje nose tkivni faktor s hemostatskom aktivnosti i njihove uporabe - Google Patents
Fosfolipidima obogaä†ene vezikule koje nose tkivni faktor s hemostatskom aktivnosti i njihove uporabe Download PDFInfo
- Publication number
- HRP20151145T1 HRP20151145T1 HRP20151145TT HRP20151145T HRP20151145T1 HR P20151145 T1 HRP20151145 T1 HR P20151145T1 HR P20151145T T HRP20151145T T HR P20151145TT HR P20151145 T HRP20151145 T HR P20151145T HR P20151145 T1 HRP20151145 T1 HR P20151145T1
- Authority
- HR
- Croatia
- Prior art keywords
- tissue factor
- microvesicle
- pharmaceutical composition
- phospholipid
- carrying
- Prior art date
Links
- 108010000499 Thromboplastin Proteins 0.000 title claims 15
- 102000002262 Thromboplastin Human genes 0.000 title claims 15
- 150000003904 phospholipids Chemical class 0.000 title claims 10
- 230000000025 haemostatic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 208000034158 bleeding Diseases 0.000 claims 3
- 230000000740 bleeding effect Effects 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 230000002947 procoagulating effect Effects 0.000 claims 3
- 206010053567 Coagulopathies Diseases 0.000 claims 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 102100027378 Prothrombin Human genes 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims 2
- 229940039716 prothrombin Drugs 0.000 claims 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims 1
- 208000013544 Platelet disease Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (18)
1. Metoda za pripravu mikrovezikule koja nosi tkivni faktor i ima prokoagulantnu aktivnost obuhvaća
(i) ekspresiju tkivnog faktora ili njegove varijante koja ima prokoagulantnu aktivnost u eukariotskoj stanici,
(ii) obnavljanje mikrovezikula koje nose tkivni faktor iz stanica iz koraka (i) i
(iii) dovođenje u dodir vezikula dobivenih u koraku (ii) s negativno nabijenim fosfolipidom u odsustvu detergenata pod uvjetima odgovarajućim za ugrađivanje navedenog fosfolipida u navedene vezikule,
pri čemu su navedene vezikule sačinjene od fosfolipidnih membrana, ili njihovih fragmenata, iz navedene eukariotske stanice.
2. Metoda u skladu s patentnim zahtjevom 1, pri čemu je eukariotska stanica stanica kvasca.
3. Metoda u skladu s bilo kojim od patentnih zahtjeva 1 do 2, pri čemu se korak dovođenja u dodir provodi koristeći 0.05 µmol negativno nabijenih fosfolipida pri čemu je sadržaj proteina u mikrovezikulama manji od 50 µg i 0.1 µmola negativno nabijenih fosfolipida pri čemu je sadržaj proteina u mikrovezikulama veći od 50 µg.
4. Metoda u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu je negativno nabijeni fosfolipid odabran iz grupe fosfolipida koji sadrži sfingozin ili fosfolipida koji sadrži glicerol.
5. Metoda u skladu s patentnim zahtjevom 4 pri čemu je fosfolipid koji sadrži glicerol fosfatidilserin.
6. Metoda u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu su navedeni tkivni faktor ili njegova varijanta koja ima prokoagulantnu aktivnost glikozilirani.
7. Metoda u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu je tkivni faktor zreli protein tkivnog faktora, poželjno ljudski zreli protein tkivnog faktora.
8. Metoda u skladu s patentnim zahtjevom 7 pri čemu tkivni faktor nosi N124A mutaciju i heksahistidinski privjesak na C terminusu.
9. Mikrovezikula koja nosi tkivni faktor dobivena koristeći metodu iz bilo kojeg od patentnih zahtjeva 1 do 8.
10. Farmaceutski sastav obuhvaća mikrovezikulu koja nosi tkivni faktor u skladu s patentnim zahtjevom 9 i farmaceutski prihvatljivi nosač.
11. Farmaceutski sastav u skladu s patentnim zahtjevom 10 nadalje obuhvaća barem jedan agens koji promovira postupak kojim se u krvi stvaraju ugrušci.
12. Farmaceutski sastav u skladu s patentnim zahtjevima 10 ili 11 pri čemu je sastav liofiliziran.
13. Mikrovezikula koja nosi tkivni faktor kako je definirana u patentnom zahtjevu 9 ili farmaceutski sastav kako je definiran u bilo kojem od patentnih zahtjeva 10 ili 11 za uporabu kao lijek.
14. Mikrovezikula koja nosi tkivni faktor kako je definirana u patentnom zahtjevu 9 ili farmaceutski sastav kako je definiran u bilo kojem od patentnih zahtjeva 10 ili 11 za uporabu u liječenju krvarenja, za promicanje cijeljenja rane ili za liječenje bolesti povezane s angiogenezom.
15. Mikrovezikula koja nosi tkivni faktor kako je definirana u patentnom zahtjevu 9 ili farmaceutski sastav kako je definiran u bilo kojem od patentnih zahtjeva 10 ili 11 za uporabu u liječenju krvarenja, pri čemu se krvarenje liječi kod subjekta odabranog iz grupe zdravog subjekta i subjekta s hemoragijskom dijatezom, pri čemu je navedena hemoragijska dijateza odabrana iz grupe nasljedne koagulopatije, stečene koagulopatije, poremećaja trombocita i njihovih kombinacija.
16. Mikrovezikula koja nosi tkivni faktor kako je definirana u patentnom zahtjevu 9 ili farmaceutski sastav kako je definiran u bilo kojem od patentnih zahtjeva 10 ili 11 za uporabu u skladu s bilo kojim od patentnih zahtjeva 14 ili 15 pri čemu se mikrovezikula koja nosi tkivni faktor ili farmaceutski sastav primjenjuju topički.
17. Uporaba mikrovezikule koja nosi tkivni faktor kako je definirana u patentnom zahtjevu 9 za određivanje protrombinskog vremena u uzorku.
18. Komplet za određivanje protrombinskog vremena obuhvaća mikrovezikulu kako je definirana u patentnom zahtjevu 9.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382085A EP2380905A1 (en) | 2010-04-19 | 2010-04-19 | Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof |
| PCT/EP2011/056219 WO2011131658A1 (en) | 2010-04-19 | 2011-04-19 | Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof |
| EP11714990.6A EP2560991B1 (en) | 2010-04-19 | 2011-04-19 | Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151145T1 true HRP20151145T1 (hr) | 2015-12-18 |
Family
ID=42541341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151145TT HRP20151145T1 (hr) | 2010-04-19 | 2015-10-28 | Fosfolipidima obogaä†ene vezikule koje nose tkivni faktor s hemostatskom aktivnosti i njihove uporabe |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8735351B2 (hr) |
| EP (2) | EP2380905A1 (hr) |
| JP (1) | JP5857035B2 (hr) |
| KR (1) | KR101884954B1 (hr) |
| CN (1) | CN102892781B (hr) |
| AU (1) | AU2011244379B2 (hr) |
| BR (1) | BR112012026907A2 (hr) |
| CA (1) | CA2796266C (hr) |
| CY (1) | CY1116940T1 (hr) |
| DK (1) | DK2560991T3 (hr) |
| ES (1) | ES2553228T3 (hr) |
| HR (1) | HRP20151145T1 (hr) |
| HU (1) | HUE025837T2 (hr) |
| MX (1) | MX2012012135A (hr) |
| PL (1) | PL2560991T3 (hr) |
| PT (1) | PT2560991E (hr) |
| RU (1) | RU2595406C2 (hr) |
| SI (1) | SI2560991T1 (hr) |
| WO (1) | WO2011131658A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2745852A1 (en) * | 2012-12-21 | 2014-06-25 | Thrombotargets Europe, S.L. | Sealant compositions |
| EP2759305A1 (en) * | 2013-01-24 | 2014-07-30 | Thrombotargets Europe, S.L. | Hemostatic compositions |
| US9687511B2 (en) * | 2015-03-06 | 2017-06-27 | Vivex Biomedical, Inc. | Acellular biologic composition and method of manufacture |
| CN106692984B (zh) * | 2016-12-08 | 2020-02-18 | 武汉大学 | 一种基于细胞源性微囊泡的肿瘤靶向递送载体及制备方法和应用 |
| KR101999818B1 (ko) * | 2017-07-26 | 2019-07-12 | ㈜로제타엑소좀 | 소수성 상호작용을 이용한 세포밖 소포체의 분리방법 |
| CN108159421B (zh) * | 2018-02-05 | 2021-05-18 | 苏州大学 | 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途 |
| WO2019185874A1 (en) * | 2018-03-30 | 2019-10-03 | Exosomics S.p.A. | Use of hollow fibers to obtain blood or a blood derivative impoverished from blood cells and platelets derived extracellular vesicles |
| CN109293780B (zh) * | 2018-09-04 | 2021-05-07 | 厦门宏谱福生物科技有限公司 | 一种人组织因子凝血复合物及其制备方法 |
| CN113134014B (zh) * | 2020-01-20 | 2023-09-26 | 医微细胞生物技术(广州)有限公司 | 囊泡在制备血友病药物中的应用 |
| KR20210117192A (ko) | 2020-03-16 | 2021-09-28 | 주식회사 엑소스템텍 | 기능성 엑소좀 제조를 위한 십자류 여과장치의 새로운 용도 |
| CN112322583B (zh) * | 2020-09-28 | 2024-02-02 | 上海思路迪生物医学科技有限公司 | 基于凝血的细胞外囊泡捕获技术 |
| CN112843072A (zh) * | 2021-01-12 | 2021-05-28 | 山东省科学院生物研究所 | 磷脂在调控血管生成方面的应用 |
| KR102431378B1 (ko) * | 2021-03-25 | 2022-08-09 | 인천대학교 산학협력단 | 세포밖 소포체의 표면 단백질 및 핵산 분석방법 |
| CN113117138A (zh) * | 2021-05-19 | 2021-07-16 | 中国石油大学(华东) | 负载组织因子及二氧化硅的胶原蛋白水凝胶止血敷料 |
| CN113262323A (zh) * | 2021-05-19 | 2021-08-17 | 中国石油大学(华东) | 负载组织因子的碳酸钙微粒自推动止血敷料 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL63270A0 (en) | 1980-08-05 | 1981-10-30 | Univ Leland Stanford Junior | Eukaryotic autonomously replicating segment |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US5223427A (en) | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| US6130074A (en) | 1992-06-01 | 2000-10-10 | American Cyanamid Company Five Giralda Farms | Recombinant insect virus with reduced capacity for host-to-host transmission in the environment and methods to produce said virus |
| ATE398679T1 (de) | 1992-07-07 | 2008-07-15 | Japan Tobacco Inc | Verfahren zur transformation einer monokotyledon pflanze |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| AU7129598A (en) * | 1997-04-23 | 1998-11-13 | Instrumentation Laboratory S.P.A. | Recombinant rabbit tissue factor based prothrombin time reagent |
| US6399384B1 (en) | 1999-09-17 | 2002-06-04 | Reneuron Limited | Conditional immortalization of cells |
| US6645768B1 (en) * | 2000-10-27 | 2003-11-11 | Biomerieux, Inc. | Reagent and kit for determining global coagulability and hemostatic potential |
| US7622437B2 (en) * | 2000-11-20 | 2009-11-24 | The Board Of Trustees Of The University Of Illinois | Tissue factor compositions and methods |
| US20030084482A1 (en) | 2001-06-08 | 2003-05-01 | Gerald Hall | Production of proteins in plants |
| JP2005510207A (ja) | 2001-07-27 | 2005-04-21 | イコン ジェネティクス インコーポレイティッド | 人及び動物の治療用又は診断用タンパク質を製造するための、アラビドプシスの工業的利用 |
| US20050221414A1 (en) * | 2004-03-31 | 2005-10-06 | Katalin Varadi | Kit for measuring the thrombin generation in a sample of a patient's blood or plasma |
| US20070292490A1 (en) | 2004-06-25 | 2007-12-20 | Valentin Negrouk | Production of tissue factor in plants |
| US7148067B2 (en) * | 2004-08-31 | 2006-12-12 | The Board Of Trustees Of The University Of Illinois | Thromboplastin reagents |
| JP2007091599A (ja) * | 2005-09-27 | 2007-04-12 | Shino Test Corp | 血液凝固反応促進剤 |
| JP5073270B2 (ja) | 2006-11-14 | 2012-11-14 | シスメックス株式会社 | 凝固検査用試薬及びその製造方法 |
| EP1939218A1 (en) | 2006-12-29 | 2008-07-02 | Thrombotargets Europe, S.L. | Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof |
-
2010
- 2010-04-19 EP EP10382085A patent/EP2380905A1/en not_active Withdrawn
-
2011
- 2011-04-19 PT PT117149906T patent/PT2560991E/pt unknown
- 2011-04-19 CA CA2796266A patent/CA2796266C/en not_active Expired - Fee Related
- 2011-04-19 PL PL11714990T patent/PL2560991T3/pl unknown
- 2011-04-19 EP EP11714990.6A patent/EP2560991B1/en active Active
- 2011-04-19 SI SI201130650A patent/SI2560991T1/sl unknown
- 2011-04-19 ES ES11714990.6T patent/ES2553228T3/es active Active
- 2011-04-19 HU HUE11714990A patent/HUE025837T2/en unknown
- 2011-04-19 JP JP2013505451A patent/JP5857035B2/ja not_active Expired - Fee Related
- 2011-04-19 BR BR112012026907A patent/BR112012026907A2/pt not_active Application Discontinuation
- 2011-04-19 CN CN201180024574.7A patent/CN102892781B/zh not_active Expired - Fee Related
- 2011-04-19 WO PCT/EP2011/056219 patent/WO2011131658A1/en active Application Filing
- 2011-04-19 AU AU2011244379A patent/AU2011244379B2/en not_active Ceased
- 2011-04-19 RU RU2012148903/10A patent/RU2595406C2/ru active
- 2011-04-19 KR KR1020127030201A patent/KR101884954B1/ko active IP Right Grant
- 2011-04-19 DK DK11714990.6T patent/DK2560991T3/en active
- 2011-04-19 MX MX2012012135A patent/MX2012012135A/es active IP Right Grant
- 2011-04-19 US US13/642,491 patent/US8735351B2/en not_active Expired - Fee Related
-
2015
- 2015-10-28 HR HRP20151145TT patent/HRP20151145T1/hr unknown
- 2015-11-16 CY CY20151101029T patent/CY1116940T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011244379B2 (en) | 2016-06-09 |
| CA2796266C (en) | 2018-06-05 |
| US8735351B2 (en) | 2014-05-27 |
| KR20130093508A (ko) | 2013-08-22 |
| EP2380905A1 (en) | 2011-10-26 |
| EP2560991B1 (en) | 2015-08-19 |
| BR112012026907A2 (pt) | 2017-01-10 |
| JP5857035B2 (ja) | 2016-02-10 |
| CN102892781A (zh) | 2013-01-23 |
| MX2012012135A (es) | 2013-02-27 |
| RU2012148903A (ru) | 2014-05-27 |
| CY1116940T1 (el) | 2017-04-05 |
| DK2560991T3 (en) | 2015-11-02 |
| HUE025837T2 (en) | 2016-04-28 |
| SI2560991T1 (sl) | 2016-06-30 |
| CA2796266A1 (en) | 2011-10-27 |
| KR101884954B1 (ko) | 2018-08-02 |
| PL2560991T3 (pl) | 2016-01-29 |
| EP2560991A1 (en) | 2013-02-27 |
| WO2011131658A1 (en) | 2011-10-27 |
| CN102892781B (zh) | 2015-09-02 |
| ES2553228T3 (es) | 2015-12-07 |
| US20130059782A1 (en) | 2013-03-07 |
| RU2595406C2 (ru) | 2016-08-27 |
| PT2560991E (pt) | 2015-11-20 |
| JP2013525326A (ja) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151145T1 (hr) | Fosfolipidima obogaä†ene vezikule koje nose tkivni faktor s hemostatskom aktivnosti i njihove uporabe | |
| Edwards et al. | Functional analysis reveals angiogenic potential of human mesenchymal stem cells from Wharton’s jelly in dermal regeneration | |
| Bonté | Skin moisturization mechanisms: new data | |
| JP2013525326A5 (hr) | ||
| US20200289583A1 (en) | Use of umbilical cord blood derived exosomes for tissue repair | |
| ES2769268T3 (es) | Extracto sinérgico de Palmaria palmata | |
| BR112017006410A2 (pt) | método e composição para a produção de anti-inflamatórios/anticatabólicos e agentes regeneradores de fluido fisiológico autólogo | |
| ES2721179T3 (es) | Composiciones cosméticas y farmacéuticas a base de líquido de incubación de pescado | |
| WO2023015533A1 (zh) | 一种合成肽以及它们的美容组合物或药用组合物及用途 | |
| Wang et al. | Adipose Mesenchymal Stem Cell Derived Exosomes Promote Keratinocytes and Fibroblasts Embedded in Collagen/Platelet‐Rich Plasma Scaffold and Accelerate Wound Healing | |
| CN105395407A (zh) | 以海洋材料为主的滢润防衰老精华液及滢润防衰老化妆品 | |
| WO2020070700A4 (en) | Compositions comprising small extracellular vesicles derived from umbilical cord blood mononuclear cells with anti-inflammatory and immunomodulatory properties and process for obtaining them | |
| CN102379838A (zh) | 一种舒缓静颜化妆品的制备方法及应用 | |
| AR069584A1 (es) | Proteinas de elastasa recombinantes y sus metodos de preparacion y su uso | |
| CN102198156A (zh) | 用于治疗皮肤创伤之医药组合物 | |
| Tian et al. | Co-delivery of bioactive peptides by nanoliposomes for promotion of hair growth | |
| AU2014253131B2 (en) | Synergistic combination of alanine-glutamine, hyaluronic acid and an oat extract and the use thereof in a composition intended for healing wounds and repairing skin lesions | |
| CN105749333A (zh) | 一种透明质酸医用敷料及其制备方法 | |
| CN102161981A (zh) | 一种重组蛋白联合诱导骨髓间充质干细胞转变为汗腺细胞的方法 | |
| US20160129045A1 (en) | Composition for wound-healing comprising adult stem cells and elastin-like polypeptides | |
| CN101906401A (zh) | 一种在非接触条件下培养诱导成体骨髓间充质干细胞转变为汗腺细胞的方法 | |
| CH696659A5 (it) | Composizione cosmetica per il trattamento e/o la prevenzione delle smagliature della pelle | |
| CN106420391A (zh) | 一种具有紧肤袪斑功效的蚕丝蛋白面膜及其制备方法 | |
| US9662247B2 (en) | Patch for treating and alleviating symptoms of skin diseases accompanied by effusion of blood proteins | |
| JP2020513007A (ja) | 皮膚損傷の処置に使用するための細菌セクレトーム |